Luisa M Stamm, MD, PhD, further discusses MK-8527 and islatravir-based regimens in HIV research.
Luisa M Stamm, MD, PhD
Advertisement
Associate Vice President of Infectious Disease Clinical Research and Section Head for HIV at Merck.
Articles by Luisa M Stamm, MD, PhD
At IAS 2025, Luisa Stamm, MD, PhD, explains the NRTTI’s mechanism, study setup, and key data on HIV prevention efforts.
Advertisement
Latest Updated Articles
Merck’s MK-8527 Advances to Phase 3 for Once-Monthly HIV PreventionPublished: July 15th 2025 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Ethiopia Investigates Marburg Virus Disease Outbreak
2
Patient With Novel Strain of Avian Influenza Dies
3
Cefiderocol Shows Activity Against Difficult-to-Treat Pathogens
4
New Combination Antibiotic Emerges to Tackle Escalating Gram-Negative Resistance Threat
5
